What Аллохол-УБФ treats: main uses and benefits

Аллохол-УБФ is a multi-component formulation generally recognized as belonging to the therapeutic category of choleretics and cholagogues. Its application is relevant in therapeutic domains involving certain distressing symptoms affecting the biliary system. This generally may assist with managing symptoms related to systemic imbalance and symptoms linked to organ-specific functional stress.

The medicine is considered relevant in contexts marked by increased discomfort or tension, applied across domains where additional symptomatic support is needed. The therapeutic domain is generally considered relevant when supportive symptom management is appropriate for the biliary system. This is often applicable within clinical settings that involve acute or disruptive symptom patterns, in situations where patients experience discomfort, functional digestive issues, or need symptomatic support in contexts involving heightened systemic burden. This therapeutic class is characterized as being indicated for such scenarios.

By acting on the overall symptomatic burden, the drug supports general well-being during symptomatic phases often associated with recurrent or episodic manifestations. This may assist with supportive relief when symptoms interfere with routine activities. It contributes to easing the overall symptom load during episodes of heightened discomfort.

Quick Fact: Supports Easing Biliary Tract Discomfort

The eligibility for using Аллохол-УБФ (Allochol-UBF) is strictly defined by regulatory documents, excluding individuals with specific acute conditions and those below a certain age.

Contraindicated Populations and Conditions

Use of this medicine is absolutely contraindicated for individuals with known hypersensitivity to any of its components and for patients with several acute inflammatory or obstructive conditions. These include:

• Acute Hepatitis and Acute/Subacute Hepatic Dystrophy.
• Obstructive Jaundice (bile duct blockage).
• Acute Pancreatitis.
• Calculous Cholecystitis (gallbladder inflammation with gallstones).
• Acute exacerbation phase of Peptic Ulcer Disease.

---

Age and Special Population Eligibility

Population Group	Eligibility Status (Regulatory Basis)
Children under 12	Use is not recommended or prohibited; safety and efficacy are not established in this age group.
Pregnant Women	Use is not recommended; safety is not established due to insufficient clinical data.
Lactating/Nursing Mothers	Use is not recommended; safety is not established due to insufficient clinical data.

Eligibility for use is generally reserved for adults and adolescents (typically over 12 years of age) with chronic, non-calculous conditions, provided no other contraindications are present.

Interactions with other medicines and products

The interaction profile of Аллохол-УБФ is primarily defined by the non-specific adsorbent action of one of its core components, Activated Charcoal.

This component drives a pharmacokinetic interaction that results in the physical binding of other orally administered substances within the gastrointestinal tract. Consequently, co-administration with other oral medicines or fat-soluble vitamins leads to a documented reduction in the bioavailability and decreased systemic exposure (AUC and Cmax) of the co-administered drug.

To mitigate this reduction in absorption, regulatory documents establish a mandatory restriction on simultaneous dosing. This restriction applies broadly to a wide category of medicinal products.

Summary of Official Interaction Restrictions

Restriction Type	Description	Classification
Interacting Substances	All oral medicines and fat-soluble vitamins	Pharmacokinetic
Contraindicated Combinations	None explicitly cited in official regulatory sources	Not Applicable
Administration Rule	Must be administered 1 to 2 hours apart from any other oral medication	Mandatory Timing Separation

This required timing separation is the critical regulatory constraint for Аллохол-УБФ, designed to prevent the adsorbent effect from interfering with the intended therapeutic levels of other medications.

How Аллохол-УБФ Works

Enhancing Hepatic Secretion (Choleretic Action)

This mechanism is centered on the liver, where bile components and herbal extracts act on hepatocytes to stimulate the synthesis and outflow of bile acids. This targeted modulation of the hepatobiliary pathway increases the volume and liquidity of bile, a physiological adjustment that modulates the process of fat emulsification and digestion.

Modulating Gastrointestinal Motility (Prokinetic Effect)

The drug components influence the smooth muscle dynamics of the intestinal wall, engaging pathways that increase the frequency and strength of peristaltic contractions. This supports the regulation of digestive movement and accelerates the transit of contents, which contributes to quicker progress through the gastrointestinal system.

Adsorption in the Intestinal Lumen

Activated charcoal acts as a physical adsorbent within the intestinal lumen, binding non-selectively to various non-polar substances, including gases and certain metabolites. This mechanistic domain reduces the concentration of these materials in the gut, thereby modulating the overall environment within the lower gastrointestinal tract.

How to Use Аллохол-УБФ: General Administration Guidelines

Аллохол-УБФ is intended for oral administration as a coated tablet. The primary procedural instruction is that the medicine must be taken after meals to align with the physiological need to enhance bile flow during the digestive process.

Labeled Dosing and Administration Scope

Category	General Administration Guidelines (Adults and Children 12 and older)
Standard Dose	1 to 2 tablets per administration.
Acute/Exacerbation Dose	1 tablet per administration.
Frequency	3 to 4 times per day (Standard); 2 to 3 times per day (Acute).
Timing in Relation to Meals	Must be taken after meals.
Age-Group Rule	Children 12 years and older follow the 1 tablet, 3 times per day regimen.
Procedural Condition	The coated tablet should be swallowed whole with water.

Course Duration and Cyclic Use

Administration of the medicine is defined by specific time limits. The standard course of use is typically 3 to 4 weeks in duration. For acute episodes, the course may be extended to 1 to 2 months. The usage pattern is intermittent, meaning repeat courses are permitted after a mandatory 3-month interval has passed between the end of the previous course and the start of a new one. This ensures the medicine is used in defined cycles over time.

Procedural Structure

The protocol for intake follows a fixed structure. The required dose is taken orally after food at a defined frequency of 2 to 4 times per day. The regimen is maintained for a specific course length, and all subsequent use must adhere to the specified non-use interval. This structures the overall administrative protocol for the medicine.

Research evidence / Overview of studies for Аллохол-УБФ

Research Evidence for Supportive Functional Digestive Support

Research has explored this fixed-dose combination in studies examining outcomes related to functional status and physical discomfort. Studies monitored various outcomes, including changes in bile flow parameters and other physiological measurements. Researchers also collected patient-reported outcomes describing perceived discomfort to see how symptoms evolved in the observed populations. This research examined temporary physiological imbalance and was primarily applied in studies examining patient-reported experiences relevant in trials assessing short-term or episodic symptom patterns. Findings describe patterns observed in the studies related to bile acid secretion and subjective reporting of symptoms. The reported outcomes were short-term and based on populations included in earlier, historical studies.

---

Overview of Study Types and Strength of Evidence

The available research for this specific four-component fixed formulation is characterized by historical clinical reports and mechanistic research exploring the therapeutic actions of the individual components. Comprehensive, large-scale, and Randomized Controlled Trials (RCTs)—the type of research generally used to establish high certainty—are not systematically indexed or widely available for this precise combination in international databases. The certainty remains low due to the nature of the available studies, and the evidence quality varies across research reports. Research describes short-term changes, but the overall evidence base provides limited insight into how this fixed combination performs under rigorous assessment standards.

---

Long-Term Outcomes and Follow-Up Data

Studies were used in research exploring how symptoms change over defined time intervals, often focusing on short-term symptom patterns. However, the follow-up durations were limited in the available studies, focusing mostly on short-term or intermediate periods. Research indicates that long-term effects are not fully established. There is limited information for long-term outcomes, and the evidence base does not provide comprehensive insight into the patterns of response or potential effects over extended time intervals.

---

Research in Specific Patient Groups

The available data primarily describe patterns observed in the adult populations studied during the original research. Research on the individual components included studies of healthy adult volunteers or specialized animal models. Data for certain groups remain insufficient; evidence in special populations like children, adolescents, or older adults is limited, and subgroup findings are uncertain. Comparative evidence is lacking for patients with significant co-existing medical conditions, meaning results apply only to the populations studied.

---

What is Still Uncertain About the Evidence Base

The main gap in the research base for Аллохол-УБФ is the documented absence of modern, gold-standard clinical trials that would provide high certainty regarding this specific fixed combination. Evidence quality varies across studies, and comparative evidence is lacking. Research highlights what is known—and what is still uncertain. Findings describe group patterns, not personal outcomes, and studies help show what has been observed so far, but research does not determine whether an individual will respond similarly. Comparative evidence is lacking, and the research provides limited information for long-term outcomes.

Key Studies & References

1. State Register of Medicinal Products of the Russian Federation: Аллохол
2. Cooperative Interaction of Phenolic Acids and Flavonoids Contained in Activated Charcoal with Herb Extracts, Involving Cholesterol, Bile Acid, and FXR/PXR Activation in Broilers Fed with Mycotoxin-Containing Diets
3. Activated Charcoal: Indications for single-dose activated charcoal administration in acute overdose

Common questions about Аллохол-УБФ (FAQ)

Q: What is the purpose of Аллохол-УБФ?

A: This medication is traditionally utilized to support the digestive process, primarily through actions affecting bile flow. It is often considered in instances of certain chronic conditions related to the gallbladder and bile ducts, aiming to promote choleretic and cholekinetic effects.

---

Q: Can I take Аллохол-УБФ if I have gallstones?

A: The presence of gallstones, particularly if they are obstructing the bile ducts, may be a contraindication for using this product. Use in individuals with cholelithiasis should be carefully evaluated by a healthcare professional, as it may influence bile flow.

---

Q: What are the main ingredients in Аллохол-УБФ?

A: The composition of this product includes dried animal bile, garlic powder, extract of stinging nettle leaves, and activated charcoal. These components are combined to provide the intended therapeutic action.

---

Q: How does Аллохол-УБФ work in the body?

A: The action is believed to be related to the components influencing the production and secretion of bile by the liver cells, and promoting the movement of bile into the digestive tract. Activated charcoal is included for its adsorptive properties within the gastrointestinal system.

---

Q: Are there any known side effects associated with Аллохол-УБФ?

A: Like many substances, potential side effects may be experienced. Commonly reported effects in available data include diarrhea or allergic reactions. It is important to consult a healthcare provider for a complete understanding of potential effects.

---

Q: Is it safe to take Аллохол-УБФ with other medications?

A: Potential interactions with other drugs exist, especially with medications that influence bile acid absorption or metabolism. Consulting a healthcare professional is necessary to evaluate all concurrent medications and determine the safety of combining them.

---

Q: What restrictions should I be aware of when using this medication?

A: It is generally advised not to use this product in cases of acute hepatitis, acute pancreatitis, obstructive jaundice, or acute enterocolitis. The full list of contraindications should be reviewed by a healthcare professional before use.

Storage Requirements

To ensure product stability, Аллохол-УБФ must be stored at a temperature not exceeding 25 C.

Condition	Requirement
Temperature Maximum	le 25 C
Protection	Store in a dry place and protected from light.
Child Safety	Keep out of the reach of children.

---

Stability and Disposal

The product's shelf-life is 4 years, provided the specified storage conditions are strictly followed. It is officially instructed that the medicine must not be used after the expiration date indicated on the package. Disposal of any unused or expired product should be conducted according to local waste requirements.